Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an…
GA Depot
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
Recommended Posts
- New AI partnership targets earlier MS diagnosis using circular RNA
- Privosegtor optic neuritis clinical trial design gains FDA agreement
- In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS
- Bike MS in Texas – largest of events in US – raises over $9M for research, care
- Tampons could offer way to monitor multiple sclerosis nerve damage